EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Artificial Intelligence and Virtual Screening to Identify Small Molecules Inhibiting Transglutaminase 2 for Investigation and Treatment of Breast Cancer

Carlo M Bergamini iD, Niel M Henriksen iD, Brianna Ryan iD, Taylor A Prince iD, Anna Terrazzan iD, Pietro Ancona iD, Cristina Zuccato iD, Gianluca Aguiari iD, Valentina Rosta, Jeffrey W Keillor iD, Alessandro Trentini iD, Nicoletta Bianchi iD

ChemBioChem · 2026

DOI: 10.1002/cbic.70542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2026. Verfasst von Carlo M Bergamini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: Transglutaminases, GTP-Binding Proteins, Breast Neoplasms, Small Molecule Libraries. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo per l'Incentivazione alla Ricerca, Fondo Interdisciplinare per la Ricerca Dipartimentale FIRD2022, Fondo di Ateneo per la Ricerca Scientifica 2024.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence‐assisted virtual screening enables identification of chemically diverse bioactive small molecules. We targeted transglutaminase 2 (TG2), a multifunctional protein associated with mesenchymal‐like features in breast cancer. Approximately 10 million compounds were screened against the catalytic site of open TG2 using the AtomNet structure‐based deep‐learning model. The top 30,000 candidates underwent physicochemical and structural filtering, diversity clustering, and manual selection, yielding 84 compounds for experimental evaluation. Fourteen induced apoptosis in MCF‐7, eight retained activity in MDA‐MB‐436, and three in MDA‐MB‐231 cells, also reducing transamidase activity in cellular lysates. Chemical‐space and fingerprint analyses placed C10 , C12, and G11 outside the principal clusters of known active TG2 inhibitors, identifying structurally differentiated, nonpeptidic scaffolds. Docking into open and intermediate TG2 conformations consistently ranked G11 as the most favorable candidate, with predicted binding near the catalytic core. In a 5‐(biotinamido)pentylamine (5‐BAP‐based assay, G11 inhibited purified recombinant human TG2 with an IC 50 of 7.64 ± 2.87 μM, while an independent dimethyl casein–dansyl cadaverine assay confirmed concentration‐dependent inhibition and yielded an estimated K i of 44 ± 11 μM, assuming competitive inhibition with respect to the substrate. Finally, G11 did not significantly affect the viability of HEK293 cells, which express negligible or very low levels of TG2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TransglutaminasesGTP-Binding ProteinsBreast NeoplasmsSmall Molecule LibrariesEnzyme InhibitorsArtificial IntelligenceAntineoplastic AgentsHumansProtein Glutamine gamma Glutamyltransferase 2FemaleApoptosisMolecular Docking SimulationDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

artificial intelligencebreast cancersmall moleculestransglutaminase 2 inhibitorvirtual screen

Substanzen

Protein Glutamine gamma Glutamyltransferase 2TransglutaminasesGTP-Binding ProteinsSmall Molecule LibrariesEnzyme InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.
  • Atomwise Inc., San Francisco, California, USA.
  • Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada.
  • Genomics Core Facility, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
  • Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  • Department of Environmental Sciences and Prevention, University of Ferrara, Ferrara, Italy.

ORCID-Profile: Carlo M Bergamini, Niel M Henriksen, Brianna Ryan, Taylor A Prince, Anna Terrazzan, Pietro Ancona, Cristina Zuccato, Gianluca Aguiari, Jeffrey W Keillor, Alessandro Trentini, Nicoletta Bianchi

Förderung

  • Fondo per l'Incentivazione alla Ricerca
  • Fondo Interdisciplinare per la Ricerca Dipartimentale FIRD2022
  • Fondo di Ateneo per la Ricerca Scientifica 2024

Zitieren

APA

Bergamini, C. M., Henriksen, N. M., Ryan, B., Prince, T. A., Terrazzan, A., Ancona, P., Zuccato, C., Aguiari, G., Rosta, V., Keillor, J. W., Trentini, A., & Bianchi, N. (2026). Artificial Intelligence and Virtual Screening to Identify Small Molecules Inhibiting Transglutaminase 2 for Investigation and Treatment of Breast Cancer. ChemBioChem. https://doi.org/10.1002/cbic.70542

Vancouver

Bergamini CM, Henriksen NM, Ryan B, Prince TA, Terrazzan A, Ancona P, et al. Artificial Intelligence and Virtual Screening to Identify Small Molecules Inhibiting Transglutaminase 2 for Investigation and Treatment of Breast Cancer. ChemBioChem. 2026. doi:10.1002/cbic.70542

BibTeX
@article{Bergamini2026,
  author = {Bergamini, Carlo M and Henriksen, Niel M and Ryan, Brianna and Prince, Taylor A and Terrazzan, Anna and Ancona, Pietro and Zuccato, Cristina and Aguiari, Gianluca and Rosta, Valentina and Keillor, Jeffrey W and Trentini, Alessandro and Bianchi, Nicoletta},
  title = {Artificial Intelligence and Virtual Screening to Identify Small Molecules Inhibiting Transglutaminase 2 for Investigation and Treatment of Breast Cancer},
  journal = {ChemBioChem},
  year = {2026},
  doi = {10.1002/cbic.70542}
}
Kostenlos starten →